Allergan (AGN) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Allergan Reports Exceptional Second Quarter 2015 Performance with 116% Increase in Net Revenue to $5.76 Billion and 29% Growth in Non-GAAP EPS to $4.41
August 6, 2015 7:01 AM EDTDUBLIN, Aug. 5, 2015 /PRNewswire/ -- Allergan plc (NYSE: AGN) reported continued exceptional performance with net revenue increasing 116 percent to $5.76 billion for the quarter ended June 30, 2015, compared to $2.67 billion in the second quarter 2014. On a non-GAAP basis, diluted earnings per share increased 29 percent to $4.41 for the second quarter 2015, compared to $3.42 in the second quarter 2014. GAAP loss per share for the second quarter 2015 was $0.80, compared to GAAP income per diluted share of $0.28 in the prior year period. GAAP results were impacted by amortization, in-process research and development impairments, acquisition-related expenses, acquisition accounting valuation related... More
FDA Approves 28 Additional Styles Of Allergan's Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants
August 5, 2015 4:26 PM EDTDUBLIN, Aug. 5, 2015 /PRNewswire/ -- Allergan, plc. (NYSE: AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market 28 additional styles of Natrelle® 410 silicone-filled breast implants, giving surgeons and patients more options to achieve desired outcomes. The FDA approved extra-full projection styles (X), along with additional low projection, low height styles (L) from the Natrelle® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implant line, for use in breast reconstruction, augmentation and revision surgery.
Logo -... More
